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A B S T R A C T
The diabetic heart has been linked with reduced endogenous levels of coenzyme Q9/10 (CoQ), an important
antioxidant and component of the electron transport chain. Although CoQ has displayed cardioprotective po-
tential in experimental models of diabetes, the impact of N-acetyl cysteine (NAC) on mitochondrial energetics
and endogenous levels of CoQ remains to be clarified. To explore these effects, high glucose-exposed H9c2
cardiomyocytes were used as an experimental model of hyperglycemia-induced cardiac injury. The results
showed that high glucose exposure caused an increased production of reactive oxygen species (ROS), which was
associated with impaired mitochondrial energetics as confirmed by a reduction of maximal respiration rate and
depleted ATP levels. These detrimental effects were consistent with significantly reduced endogenous CoQ levels
and accelerated cell toxicity. Although metformin demonstrated similar effects on mitochondrial energetics and
cell viability, NAC demonstrated a more pronounced effect in ameliorating cytosolic and mitochondrial ROS
production. Interestingly, the ameliorative effects of NAC against hyperglycemia-induced injury were linked
with its capability to enhance endogenous CoQ levels. Although such data are to be confirmed in other models,
especially in vivo studies, the overall findings provide additional evidence on the therapeutic mechanisms by
which NAC protects against diabetes-induced cardiac injury.
1. Introduction
Reactive oxygen species (ROS)-mediated myocardial injury is a
widely reported phenomenon in the diabetic state [1–3]. Chronically
elevated ROS levels can drive several pathological conditions by de-
pleting intracellular antioxidant defence systems [4]. In both humans
and animals with diabetes mellitus, enhanced generation of oxidative
stress due to excess ROS production has been associated with depleted
glutathione (GSH) levels [5,6]. This consequence has been shown to be
even worse in patients with microvascular complications [7], which
could explain the accelerated myocardial injury in a diabetic state [8].
Alternatively, N-acetylcysteine (NAC) is a thiol containing antioxidant
that is being investigated for its diverse therapeutic capabilities [9,10].
NAC is known to act broadly by neutralizing free radical-induced cel-
lular injury and blocking excess ROS production [11]. Most im-
portantly, NAC is a known precursor for GSH synthesis, and thus it
could play a major role in ameliorating diabetes associated complica-
tions, especially those linked with excess generation of oxidative stress.
Indeed, increasing studies [12–14], including reviews from our
group [9,10], have demonstrated that NAC displays a strong potential
to attenuate a diverse group of metabolic complications, including
hyperglycemia-induced myocardial injury. For example, NAC
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attenuates oxidative stress and cardiac remodeling in rats during tran-
sition from compensated left ventricular hypertrophy to heart failure
[14]. NAC could also alleviate palmitic acid-induced myocardial
apoptosis by blocking excess mitochondrial ROS production in cultured
neonatal rat cardiomyocytes [15]. In fact, impaired mitochondrial en-
ergetics that is usually accompanied by excess ROS production is re-
cognized as the key feature implicated in diabetes-induced myocardial
injury [2,16,17]. Moreover, other critical components of the mi-
tochondrial electron transport chain such as coenzyme Q9/10 (CoQ) that
are essential in the process of bioenergetics have been shown to be
compromised in the diabetic heart [18]. Beyond its importance in
bioenergetics, CoQ remains a significant antioxidant able to protect the
myocardium against oxidative stress-induced injury [19]. Interestingly,
although NAC has displayed partial cardioprotective effects in experi-
mental models of diabetes [10], the impact of NAC on mitochondrial
energetics or endogenous levels of CoQ remains mostly unknown. Thus,
the current study explored such effects in high glucose-exposed H9c2
cardiomyocytes as an experimental model of hyperglycemia-induced
cardiac injury.
2. Materials and methods
2.1. Chemicals and reagents
Embryonic ventricular rat heart derived H9c2 cardiomyoblasts
(CRL-1446) were from American Type Culture Collection (Manassas,
USA); Penicillin-Streptomycin, Dulbecco’s Modified Eagle’s Medium
(DMEM), fetal bovine serum (FBS), and Phosphate Buffered Saline
(PBS) were from Carlo Erba (Milano, Italy); dichlorfluorescein diacetate
(DCFH-DA) and MitoSOX fluorescent probes were from ThermoFisher
Scientific (Waltham, USA); Bradford and RC DC protein assay kit was
from Bio-Rad Laboratories (Hercules, USA); ViaCount was from Merck-
Millipore (Darmstadt, Germany). Seahorse XF96 microplate plates,
Seahorse XF Assay media, Seahorse XF media and Mito Stress Kits were
from Agilent (Santa Clare, USA). All other chemicals including NAC and
metformin were obtained from Sigma-Aldrich (St. Louis, USA).
2.2. Cell culture and treatment conditions
H9c2 cardiomyoblasts were cultured in DMEM supplemented with
10% FBS, 100 μg/mL penicillin and 100 μg/mL streptomycin overnight
under standard tissue culture conditions (37 °C in humidified air and
5% CO2). Cells were cultured at a seeding density of 25 000 cells/well
in 24 multi-well plates, and maintained in growth media until con-
fluency, while medium was refreshed every second day. Confluent
H9c2 cardiomyoblasts were exposed to 33mM glucose (high glucose)
for 24 h before treatment for 6 h with NAC or metformin at 1mM and
1 μM, respectively. Cells exposed to 5.5 and 33mM glucose con-
centrations served as controls for normoglycemic and hyperglycemic
states, respectively. All doses for treatment compounds and experi-
mental controls were based on previously published studies [5,20].
2.3. Cytosolic and mitochondrial ROS detection assays
Cytosolic and mitochondrial ROS production was evaluated using
flow-cytometry by means of DCFH-DA and MitoSOX fluorescent dyes,
as per already described methods [21–23]. Briefly, treated cardio-
myocytes or untreated control cells were incubated for 30min or
15min in a solution 5 μM of DCFH-DA or MitoSOX dye, respectively at
37 °C. After trypsinization, washed cells were analyzed on a Guava
Easycite flow cytometer (Millipore; Darmstadt, Germany). Most im-
portantly, flow-cytometry analysis of cytosolic ROS production was
done together with cell viability assay using ViaCount (described below
in Section 2.6), and this was based on single cell analysis for optimal
estimation of ROS in viable cells.
2.4. Assessment of mitochondrial bioenergetics
Oxygen consumption rate (OCR) was measured using the XF96
Extracellular Flux analyzer (Agilent Technologies; Santa Clare, USA), as
previously described [24]. Parameters that were measured included
basal oxygen consumption rate, ATP production, maximal respiration
rate, and spare capacity. OCR (pmol/min) was normalized with protein
content, whereas OCR was reported as absolute rates (pmoles/min for
OCR and mpH/min for ECAR/ mg protein).
2.5. CoQ quantification and oxidation status
The intracellular levels of CoQ9, which is the predominant form of
ubiquinone in murine models [25], as well as the CoQ10, which is the
well-known and predominant form in humans were quantified from
treated H9c2 cardiomyocytes based on a previously described method
[26]. Briefly, 50 μl cell suspension, approximately 200,000 cells, were
extracted adding 250 μl isopropanol and vigorously mixing before
centrifugation at 20,900 g for 2min at 4 °C. Thereafter, extracts were
injected into a high-performance liquid chromatograph (HPLC) with
Fig. 1. The impact of N-acetyl cysteine (NAC) treatment on mitochondrial and
cytosolic production of reactive oxygen species (ROS) in cultured H9c2 cardi-
omyocytes. Briefly, H9c2 cardiomyocytes were exposed to 33mM high glucose
(HG) for 24 h before treatment with NAC or metformin (MET) at a dose 1 μM for
6 h. Graphs cytosolic (A) and mitochondrial (B) ROS production. Results are
expressed as the mean of at least two independent experiments. ***p < 0.001
depicts statistical significance versus normal glucose (NG) control (5.5 mM).
#p < 0.05, ##p≤ 0.01 statistical significance versus HG control.
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electro-chemical detector (ECD) (Shiseido Co. Ltd.; Tokyo, Japan). This
system is characterized by a post-separation reducing column (Shiseido
CQR) that is capable of fully reducing eluted ubiquinone. CoQ9/10
oxidative status was expressed as percentage of ubiquinone/total CoQ9/
10, while total CoQ9/10 content in H9c2 cardiomyocytes was expressed
as μg/mg CoQ9/10 protein.
2.6. Cell viability and metabolic activity assays
Viability was estimated flow-cytometry using Millipore™ Guava
ViaCount Reagent cytotoxicity test as previously reported [21]. Briefly,
the assay makes use of a mixture of cell membrane permeable and
impermeable DNA-binding fluorescent probes, discriminated by red
and yellow color, diluted 1:10 in PBS and used to stain approximately
20,000 cells immediately before reading. The analysis of the distribu-
tion allows the discrimination of the percentage of cell debris (R−/
Y−), live cells (R+/Y−) and dead cells (R+/Y+). In addition, cell
viability was confirmed by MTT using a previously described method
[27]. The MTT assay uses colorimetric measurement of tetrazolium dye
(MTT) conversion to its insoluble formazan product to estimate meta-
bolic activity of viable cells. MTT absorbance was read at 570 nm using
a BioTek ELx800 plate reader (Winooski, USA) and Gen 5 software for
data acquisition.
2.7. Statistical analysis
Results were expressed as the mean of three independent biological
experiments with each experiment containing at least three technical
replicates. GraphPad Prism software version 6.0 (GraphPad Software,
Inc., La Jolla, USA) was used to analyze data. Comparisons between
groups were performed using one-way multivariate ANOVA followed
by a Tukey post hoc test and Student t-test where appropriate. A p-value
of ≤0.05 was considered statistically significant.
3. Results
3.1. NAC ameliorates excess ROS production in high glucose-exposed
cardiomyocytes
The hyperglycemic state is consistently linked with excessive cyto-
solic and mitochondrial ROS production, and this may lead to the
generation of oxidative stress and subsequent cellular damage. The
current findings showed that exposing H9c2 cardiomyocytes to high
glucose as a model of hyperglycemia caused a significant increase
(p < 0.001) in cytosolic and mitochondrial ROS production when
compared to the normal glucose control (Fig. 1A, B). Treatment with
NAC showed a more pronounced effect (p≤ 0.01) than metformin
(p < 0.05) in reducing excess ROS production (Fig. 1A, B).
3.2. NAC improves mitochondrial energetics in high glucose-exposed
cultured cardiomyocytes
A competent mitochondrial energetic process is essential for normal
myocardial function. High glucose-exposed cardiomyocytes demon-
strated compromised mitochondrial energetics, as depicted by mark-
edly reduced oxygen consumption rate that was accompanied by sup-
pressed ATP production and spare respiratory capacity, when compared
to cells treated with normal glucose (Fig. 2 A–D). Treatment with NAC
showed consistent results (p≤ 0.001) with metformin (p≤ 0.001) in
improving mitochondrial energetics (Fig. 2A–D).
3.3. NAC enhances endogenous CoQ levels in high glucose-exposed cultured
cardiomyocytes
In addition to its antioxidant properties, CoQ plays an important
role in the process of mitochondrial energetics by acting as an electron
carrier during oxidative phosphorylation. Although as expected that
CoQ9 levels were relatively higher than that of CoQ10 in these murine
Fig. 2. The impact of N-acetyl cysteine (NAC) treatment on mitochondrial energetics in cultured H9c2 cardiomyocytes. Briefly, H9c2 cardiomyocytes were exposed
to 33mM high glucose (HG) for 24 h before treatment with NAC or metformin (MET) at a dose 1 μM for 6 h. Graphs depict basal oxygen consumption rate (A), ATP
production (B), maximal respiration rate (C), and spare capacity (D). Results are expressed as the mean of at least two independent experiments. ***p < 0.001
depicts statistical significance versus normal glucose (NG) control (5.5 mM). ###p≤ 0.001 statistical significance versus HG control.
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derived cardiomyocytes, high glucose exposure showed consistent ef-
fect (p < 0.05) in reducing the endogenous levels for both forms of this
enzyme, when compared to normal glucose treated cells (Fig. 3A, B).
Interestingly, only treatment with NAC, not metformin, showed sig-
nificant enhancement of endogenous CoQ levels after high glucose ex-
posure (Fig. 3A, B). However, it was evident that treatment with neither
NAC nor metformin influenced the oxidation status of CoQ in these
H9c2 cardiomyocytes (Fig. 3C, D).
3.4. NAC improves metabolic activity and cell viability in high glucose-
exposed cultured cardiomyocytes
Enhanced cardiomyocyte damage due to excess ROS production is a
well-known consequence in a diabetic state. Exposure of H9c2 cardio-
myocytes to high glucose significantly reduced both metabolic activity
(p≤ 0.001) and cell viability (p≤ 0.001), when compared to normal
glucose treated cells (Fig. 4A, B). Treatment with NAC and metformin
demonstrated similar effect (p≤ 0.001) in improving metabolic ac-
tivity and cell viability of high glucose-exposed cardiomyocytes
(Fig. 4A, B).
4. Discussion
It is currently known that cardiovascular complications are the
leading cause of death in diabetic patients [28]. Independently of
atherosclerosis buildup, it has been found that hyperglycemia could
greatly impact cardiac efficiency by accelerating oxidative stress-in-
duced myocardial injury, leading to heart failure and reduced life ex-
pectancy [28,29]. For this reason, much research has focused on the
exploration of compounds with antioxidant activity to attenuate
oxidative stress and improve cardiac function in the diabetic state
[10,30]. Due to its known antioxidant properties, NAC is increasingly
explored for its cardioprotective effects against diabetes-associated
complications, especially the targeting of oxidative stress-induced cel-
lular injury [10]. Although some progress has been made in identifying
therapeutic mechanisms associated with the cardioprotective effects of
NAC in experimental models of diabetes [10], less is known regarding
its influence on mitochondrial function under hyperglycemic condi-
tions. Thus, acknowledging the contribution of impaired mitochondrial
function to increased ROS production and oxidative stress, the current
study explored the impact of NAC on maintaining cellular viability, and
improving bioenergetics under hyperglycemic conditions in cultured
H9c2 cardiomyocytes.
Over the years, high glucose-exposed H9c2 cardiomyocytes have
become a reliable model to study hyperglycemia-associated patholo-
gical abnormalities [20,31]. This experimental model has become even
more relevant for assessing the direct association between the hy-
perglycemic state and accelerated oxidative stress-induced injury, while
excluding other cardiovascular complications such as atherosclerosis
[20,31]. Certainly, exposing H9c2 exposed to elevated glucose con-
centrations for 24 h in the current study was associated with enhanced
cytosolic and mitochondrial ROS production, that was accompanied by
the impaired bioenergetics. The latter could be determined by mea-
suring basal respiration, ATP production, maximal respiration, and
spare respiratory capacity after cardiomyocytes were incubated with
high glucose. Subsequently, a clear trend showing suppressed mi-
tochondrial respiration could be identified by measuring these mi-
tochondrial energetic factors, further suggesting that compromised in-
tegrity of the electron transport chain plays a significant role in the
production of ROS and subsequent cellular injury. Supporting these
Fig. 3. The impact of N-acetyl cysteine (NAC) treatment on endogenous levels and oxidation status of Coenzyme Q9/10 (CoQ9/10) in cultured H9c2 cardiomyocytes.
Briefly, H9c2 cardiomyocytes were exposed to 33mM high glucose (HG) for 24 h before treatment with NAC or metformin (MET) at a dose 1 μM for 6 h. Graphs
depict CoQ9 (A) and CoQ10 (B) content, as well as oxidation status of CoQ9 (C) and CoQ10 (D). Results are expressed as the mean of at least two independent
experiments. *p < 0.05 depicts statistical significance versus normal glucose (NG) control (5.5 mM). ##p≤ 0.01 statistical significance versus HG control.
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findings are others showing that impaired oxidative phosphorylation
capacity in experimental models of metabolic syndrome is directly
implicated in oxidative stress-induced myocardial injury [2,16,32,33].
Nevertheless, although intracellular antioxidants were not measured in
the current study, it was clear that exposure of cardiomyocytes to hy-
perglycemia prominently affected cellular adaptive responses against
oxidative stress, as demonstrated by significant reduction in en-
dogenous CoQ levels. In this case, supplementation drug agents that
strengthen intracellular antioxidant responses, including increasing
endogenous CoQ levels remains a viable option to protect against dia-
betes-induced cardiac injury.
Interestingly, administration of NAC, together with CoQ10 and su-
peroxide dismutase mimetic has already been shown to prevent mi-
tochondrial cell dysfunction and cell death induced by D-galactosamine
in primary culture of human hepatocytes [34]. Relevant to the heart,
NAC and CoQ10 have been demonstrated to be effective in attenuating
impaired myocardial energy expenditure and oxidative stress, induced
by carbon tetrachloride intoxication in rats [35]. Consistently with CoQ
administration, NAC displays the potential to ameliorate oxidative
stress-induced toxicity by improving mitochondrial function in the
diabetic state. NAC has already been shown to enhance intracellular
antioxidants such as GSH to protect against hyperglycemia-induced
cardiomyocyte damage [5]. Thus, although intracellular antioxidants
like GSH were not tested in the current study, it was clear that NAC
could protect H9c2 cardiomyocytes against hyperglycemia-linked oxi-
dative stress by improving endogenous CoQ levels and mitochondrial
energetics. In fact, novel findings from this study suggest that en-
hancement of endogenous CoQ levels may be an important mechanism
by which NAC attenuates hyperglycemia-induced cardiomyocyte toxi-
city. These results were concomitant to improved metabolic activity,
cell viability and ATP production of cardiomyocytes under hypergly-
cemic conditions. Metformin, a well-known anti-diabetic agent, also
showed cardioprotective effects similar to NAC, however it failed to
significantly impact the endogenous CoQ levels, suggesting its limited
efficacy to efficiently trigger other adaptive responses that are im-
portant to protect against hyperglycemia-associated complications.
CoQ is known to to play a key role in the process of mitochondrial
bioenergetics, actively participating in aerobic cellular respiration,
thereby contributing to effective generation of energy in the form of
ATP, and also maintenance of redox status of cells [19,23]. Overall,
although did not impact the CoQ oxidative status, a phenomenon that
has to be further explored, the current findings suggest that NAC ad-
ministration could be an effective therapy to improve cardiac function
under diabetic conditions by enhancing adaptive responses against
oxidative stress, especially enhancement of endogenous CoQ levels.
However, before such hypothesis is accepted, it is necessary to confirm
these preliminary results in other experimental models, especially in
vivo settings.
5. Conclusion
Accelerated oxidative stress associated with impaired mitochondrial
function is one of the prominent mechanisms implicated in hypergly-
cemia-induced cardiac injury. In fact, due to its contribution to excess
ROS production, impaired mitochondrial energetics represents an im-
portant mechanism to be explored to understand the impact of hy-
perglycemia on the heart. This study provides important new in-
formation regarding the protective potential of NAC against
hyperglycemia-induced cardiomyocyte injury, decreased mitochondrial
energetics and endogenous CoQ levels. We propose that enhancement
of endogenous levels of CoQ may be an important mechanism by which
NAC improves mitochondrial function under hyperglycemic conditions,
and thus ameliorate oxidative stress-linked myocardial toxicity.
However, the missing link may be to understand the mechanism by
which NAC could impact mitochondrial function by enhancing en-
dogenous CoQ levels, and for this perhaps functional studies are re-
quired that target CoQ biosynthesis pathways. It also remains important
to know how the combination of metformin and NAC could compare to
the use of each compound as a monotherapy.
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